IP Library Granted Patent US 9,090,924
Granted Patent B2
US 9,090,924 · App. 13/575,145 · Granted Jul 28, 2015

Nucleic acid construct comprising pyripyropene biosynthetic gene cluster and marker gene

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,090,924
App. No.
13/575,145
Granted
Jul 28, 2015
Kind
B2
Abstract

There is provided a nucleic acid construct comprising a pyripyropene biosynthetic gene cluster and a marker gene. The nucleic acid construct according to the present invention provides an inexpensive and highly productive method for producing pyripyropene.

Claims (12)

1. A method for producing pyripyropenes comprising culturing a transformed host cell obtained by transforming a heterologous host cell with a heterologous nucleic acid construct and collecting pyripyropenes from the culture, wherein said heterologous nucleic acid construct comprises a pyripyropene biosynthetic gene cluster and a marker gene simultaneously or separately, and wherein said pyripyropene biosynthetic gene cluster comprises at least one nucleotide sequence selected from (I) to (IV) below:

(I) the nucleotide sequence of positions 2911 to 27797 in the nucleotide sequence set forth in SEQ ID NO: 266;

(II) a nucleotide sequence which is capable of hybridizing with every nucleotide in the full length complementary sequence of positions 2911 to 27797 in SEQ ID NO: 266 under stringent conditions wherein said stringent conditions comprise washing with 2× saline-sodium citrate (SSC) buffer and 0.5% sodium dodecyl sulfate (SDS) at 60° C. for 20 minutes, and then washing with 0.2×SSC and 0.1% SDS at 60° C. for 15 minutes,

wherein positions of the nucleotide sequence corresponding to positions 3342 to 5158 in SEQ ID NO: 266 encode a protein having CoA ligase activity, positions of the nucleotide sequence corresponding to positions 5382 to 12777 in SEQ ID NO: 266 encode a protein having LovB-like polyketide synthase activity, positions of the nucleotide sequence corresponding to positions 13266 to 15144 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-1 activity, positions of the nucleotide sequence corresponding to positions 16220 to 18018 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-2 activity, positions of the nucleotide sequence corresponding to positions 18506 to 19296 in SEQ ID NO: 266 encode a protein having Cyclase activity, positions of the nucleotide sequence corresponding to positions 19779 to 21389 in SEQ ID NO: 266 encode a protein having FAD-dependent monooxygenase activity, positions of the nucleotide sequence corresponding to positions 21793 to 22877 in SEQ ID NO: 266 encode a protein having UbiA-like prenyltransferase activity, positions of the nucleotide sequence corresponding to positions 23205 to 24773 in SEQ ID NO: 266 encode a protein having Acetyltransferase activity, and positions of the nucleotide sequence corresponding to positions 25824 to 27178 in SEQ ID NO: 266 encode a protein having Acetyltransferase-2 activity;

III) a nucleotide sequence comprising positions 2911 to 27797 of the nucleotide sequence set forth in SEQ ID NO: 266 having no more than 10 nucleotides deleted, substituted, inserted, or added in each of the nucleotide sequences corresponding to positions 3342 to 5158, 5382 to 12777, 13266 to 15144, 16220 to 18018, 18506 to 19296, 19779 to 21389, 21793 to 22877, 23205 to 24773, and 258124 to 27178 of the nucleotide sequence set forth in SEQ ID NO: 266,

wherein positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 3342 to 5158 in SEQ ID NO: 266 encode a protein having CoA ligase activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 5382 to 12777 in SEQ ID NO: 266 encode a protein having LovB-like polyketide synthase activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 13266 to 15144 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-1 activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 16220 to 18018 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-2 activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 18506 to 19296 in SEQ ID NO: 266 encode a protein having Cyclase activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 19779 to 21389 in SEQ ID NO: 266 encode a protein having FAD-dependent monooxygenase activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 21793 to 22877 in SEQ ID NO: 266 encode a protein having UbiA-like prenyltransferase activity, positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 23205 to 24773 in SEQ ID NO: 266 encode a protein having Acetyltransferase activity, and positions of the nucleotide sequence having no more than 10 nucleotides deleted, substituted, inserted, or added and corresponding to positions 25824 to 27178 in SEQ ID NO: 266 encode a protein having Acetyltransferase-2 activity; and

IV) a nucleotide sequence comprising at least 95% identity to each of the nucleotide sequences corresponding to positions 3342 to 5158, 5382 to 12777, 13266 to 15144, 16220 to 18018, 18506 to 19296, 19779 to 21389, 21793 to 22877, 23205 to 24773, and 258124 to 27178 of the nucleotide sequence set forth in SEQ ID NO: 266

wherein positions of the nucleotide sequence corresponding to positions 3342 to 5158 in SEQ ID NO: 266 encode a protein having CoA ligase activity, positions of the nucleotide sequence corresponding to positions 5382 to 12777 in SEQ ID NO: 266 encode a protein having LovB-like polyketide synthase activity, positions of the nucleotide sequence corresponding to positions 13266 to 15144 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-1 activity, positions of the nucleotide sequence corresponding to positions 16220 to 18018 in SEQ ID NO: 266 encode a protein having Cytochrome P450 monooxygenase-2 activity, positions of the nucleotide sequence corresponding to positions 18506 to 19296 in SEQ ID NO: 266 encode a protein having Cyclase activity, positions of the nucleotide sequence corresponding to positions 19779 to 21389 in SEQ ID NO: 266 encode a protein having FAD-dependent monooxygenase activity, positions of the nucleotide sequence corresponding to positions 21793 to 22877 in SEQ ID NO: 266 encode a protein having UbiA-like prenyltransferase activity, positions of the nucleotide sequence corresponding to positions 23205 to 24773 in SEQ ID NO: 266 encode a protein having Acetyltransferase activity, and positions of the nucleotide sequence corresponding to positions 25824 to 27178 in SEQ ID NO: 266 encode a protein having Acetyltransferase-2 activity.

2. The method of claim 1 , comprising culturing a transformant, wherein said gene cluster and said marker gene are on the same heterologous nucleic acid.

3. A method for producing pyripyropenes comprising culturing a transformed host cell obtained by transforming a heterologous host cell with a heterologous nucleic acid construct and collecting pyripyropenes from the culture, wherein said heterologous nucleic acid construct comprises a pyripyropene biosynthetic gene cluster and a marker gene, and wherein said pyripyropene biosynthetic gene cluster comprises the nucleotide sequence of positions 1 to 25000 of the nucleotide sequence set forth in SEQ ID NO: 266.

4. The method of claim 1 , wherein said pyripyropene biosynthetic gene cluster comprises the nucleotide sequence of part (I).

5. The method of claim 1 , wherein said pyripyropene biosynthetic gene cluster comprises the nucleotide sequence of part (III).

Assignments (3)
CHANGE OF NAME Recorded Feb 7, 2024
From: MITSUI CHEMICALS AGRO, INC.
To: MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC.
Reel/Frame 066508/0493 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2022
From: MEIJI SEIKA PHARMA CO., LTD.
To: MMAG CO., LTD.
Reel/Frame 060582/0126 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2012
From: AIHARA, SATO; SUMIDA, NAOMI; MURASHIMA, KOICHIRO; YANAI, KOUJI; ANZAI, HIROYUKI; YAMAMOTO, KENTARO
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 028988/0403 →